Evolus sees Q4 revenue $61M, consensus $56.97M

Sees FY23 revenue $202M, consensus $198.03M. Evolus announced its preliminary, unaudited net revenue for the Q4 and FY23. “We believe the preliminary results of the Q4 and FY23 are clear indications of our strong operational execution and significant market share gains resulting from deeper penetration of the neurotoxin market in the U.S. with Jeuveau and expansion of our neurotoxin brand, Nuceiva, in Europe,” said David Moatazedi, President and CEO. “We are thrilled to have achieved record results and exceeded our guidance for the year, positioning us to carry this strong momentum and drive growth into 2024.”